Author
Yunhua Liao
Other affiliations: Guangxi University
Bio: Yunhua Liao is an academic researcher from Guangxi Medical University. The author has contributed to research in topics: Medicine & Renal function. The author has an hindex of 4, co-authored 6 publications receiving 1605 citations. Previous affiliations of Yunhua Liao include Guangxi University.
Papers
More filters
••
TL;DR: The prevalence of chronic kidney disease in China was high in north and southwest and southwest regions compared with other regions, and economic development was independently associated with the presence of albuminuria.
1,588 citations
••
Peking University1, Zhengzhou University2, Anhui Medical University3, First Affiliated Hospital of Xinjiang Medical University4, Huazhong University of Science and Technology5, Zhejiang University6, Fujian Medical University7, China Three Gorges University8, Kunming Medical University9, Shanghai Jiao Tong University10, Harbin Medical University11, Lanzhou University12, Shandong University13, Second Military Medical University14, Shanxi Medical University15, The University of Nottingham Ningbo China16, Southeast University17, Hebei Medical University18, Guangxi Medical University19, Fudan University20
TL;DR: A nationwide, cross-sectional survey of adult patients who were admitted to hospital in 2013 in academic or local hospitals from 22 provinces in mainland China aimed to evaluate the burden of AKI and assess the availability of diagnosis and treatment and found that 1·4-2·9 million people with AKI were admitted in China in 2013.
292 citations
••
TL;DR: The prevalence of dyslipidemia among Chinese adults was high but awareness, treatment, and control of dys Lipidemia were low, and urban high income earners and rural medium income earners show higher prevalence.
260 citations
••
TL;DR: Delayed AKI recognition and being located in northern China were independent risk factors for in-hospital mortality, and referral to nephrology providers was an independent protective factor.
49 citations
•
TL;DR: Results indicate that CMIP rs16955379 SNP may be a genetic susceptibility gene for dyslipidemia and poor renal outcome in IgAN.
Abstract: Immunoglobulin A nephropathy (IgAN) is among the most common primary glomerular diseases. The prognosis in IgAN is affected by dyslipidemia, a risk factor for cardiovascular disease. The c-Maf inducing protein (CMIP) gene has been found to be associated with lipid metabolism. But the association between the CMIP rs16955379 single nucleotide polymorphism (SNP) and dyslipidemia or the related clinicopathological features in IgAN have not been reported thus far. The present study investigated the correlation between them. The CMIP rs16955379 SNP genotypes of 300 subjects with IgAN recruited from the First Affiliated Hospital of Guangxi Medical University were identified by polymerase chain reaction and direct sequencing. Compared with the control (normal lipid) group, the dyslipidemia group with IgAN had higher blood uric acid, serum creatinine, blood urea nitrogen and urinary protein quantity, higher proportions of mesangial cell proliferation and renal tubular atrophy/interstitial fibrosis (IFTA), and a lower estimated glomerular filtration rate and serum albumin. The frequencies of the CMIP rs16955379 SNP TT genotype and T allele in the dyslipidemia group were higher than in the control group. Triglyceride, apolipoprotein A1 (ApoA1), ApoA1/B, incidences of mesangial cell proliferation, and IFTA were higher in TT genotype carriers than in CC/CT genotype carriers. Serum lipid profiles and dyslipidemia were significantly associated with renal dysfunction and IFTA. IgAN patients with the TT genotype were more likely to have dyslipidemia, renal dysfunction and IFTA (P < 0.05 for all above). These results indicate that CMIP rs16955379 SNP may be a genetic susceptibility gene for dyslipidemia and poor renal outcome in IgAN.
8 citations
Cited by
More filters
••
TL;DR: Screening and intervention can prevent chronic kidney disease, and where management strategies have been implemented the incidence of end-stage kidney disease has been reduced, but awareness of the disorder remains low in many communities and among many physicians.
3,207 citations
••
TL;DR: The burden of CKD was much higher than expected for the level of development, whereas the disease burden in western, eastern, and central sub-Saharan Africa, east Asia, south Asia, central and eastern Europe, Australasia, and western Europe was lower than expected.
2,370 citations
••
TL;DR: CKD has a high global prevalence with a consistent estimated global CKD prevalence of between 11 to 13% with the majority stage 3, and future research should evaluate intervention strategies deliverable at scale to delay the progression of CKD and improve CVD outcomes.
Abstract: © 2016 Hill et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Chronic kidney disease (CKD) is a global health burden with a high economic cost to health systems and is an independent risk factor for cardiovascular disease (CVD). All stages of CKD are associated with increased risks of cardiovascular morbidity, premature mortality, and/or decreased quality of life. CKD is usually asymptomatic until later stages and accurate prevalence data are lacking. Thus we sought to determine the prevalence of CKD globally, by stage, geographical location, gender and age. A systematic review and meta-analysis of observational studies estimating CKD prevalence in general populations was conducted through literature searches in 8 databases. We assessed pooled data using a random effects model. Of 5,842 potential articles, 100 studies of diverse quality were included, comprising 6,908,440 patients. Global mean(95%CI) CKD prevalence of 5 stages 13.4%(11.7-15.1%), and stages 3-5 was 10.6%(9.2-12.2%). Weighting by study quality did not affect prevalence estimates. CKD prevalence by stage was Stage-1 (eGFR>90+ACR>30): 3.5% (2.8-4.2%); Stage-2 (eGFR 60-89+ACR>30): 3.9% (2.7-5.3%); Stage-3 (eGFR 30-59): 7.6% (6.4-8.9%); Stage-4 = (eGFR 29-15): 0.4% (0.3-0.5%); and Stage-5 (eGFR<15): 0.1% (0.1-0.1%). CKD has a high global prevalence with a consistent estimated global CKD prevalence of between 11 to 13% with the majority stage 3. Future research should evaluate intervention strategies deliverable at scale to delay the progression of CKD and improve CVD outcomes.
2,321 citations
••
TL;DR: The findings show the prevalence of kidney disease on admission and the development of AKI during hospitalization in patients with COVID-19 is high and is associated with in-hospital mortality, and clinicians should increase their awareness of kidney patients with severe CO VID-19.
1,994 citations
••
TL;DR: Stroke and ischaemic heart disease were the leading causes of death and DALYs at the national level in China in 2017, and China has made substantial progress in reducing the burden of many diseases and disabilities.
1,874 citations